Cervical Dystonia Market

Market Overview:

The 7 major cervical dystonia markets reached a value of US$ 148.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 270.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.61% during 2024-2034.

The cervical dystonia market has been comprehensively analyzed in IMARC's new report titled "Cervical Dystonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cervical dystonia, which is also known as spasmodic torticollis, refers to a neurological disorder that causes involuntary muscle contractions in the neck, leading to aberrant movements and postures of the neck and head. Depending on the causative factor, cervical dystonia is classified as primary (idiopathic) and secondary (symptomatic). The symptoms of this disease can range from mild to severe. Some common indications include head twisting in various directions, jerking motion of the head, chin towards the shoulder, neck pain extending to the shoulders, etc. Additionally, individuals suffering from the ailment may experience disabling pain, fatigue, a raised shoulder, hand tremors, enlargement of the neck muscle, headaches, etc. The diagnosis of the condition is based on a review of the patient's clinical features, medical history, and physical exam. The healthcare provider may also perform several diagnostic tests and procedures, such as blood workups, magnetic resonance imaging (MRI), electromyography (EMG), etc., to confirm a diagnosis and dismiss other possible causes of underlying symptoms.

The rising prevalence of neurological disorders, which cause abnormalities in the basal ganglia or other brain areas that control body movement, is primarily driving the cervical dystonia market. In addition to this, the increasing incidence of various risk factors, including advancing age, head or neck trauma, family history of dystonia, genetic mutations, etc., is also bolstering the market growth. Moreover, the widespread adoption of effective medications, such as anticholinergics, GABAergics, anticonvulsants, dopaminergics, etc., to treat disease symptoms is acting as another significant growth-inducing factor. Apart from this, the inflating application of biofeedback therapy, which helps improve mind-body connection and relax muscles to regulate involuntary body processes, is also propelling the market growth. Additionally, multiple key players are making extensive investments in R&D activities to launch new assessment tools with excellent sensitivity and specificity for early disease diagnosis. This, in turn, is creating a positive outlook for the market. Furthermore, the emerging popularity of deep brain stimulation for treating the ailment on account of its several associated benefits, such as reduced muscle contractions and long-lasting relief from symptoms, is expected to drive the cervical dystonia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cervical dystonia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cervical dystonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cervical dystonia market in any manner.

Recent Developments:

• In August 2023, Revance Therapeutics, Inc. announced that the United States FDA had approved the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) injection for the treatment of cervical dystonia in adults.
• In August 2023, AEON Biopharma, Inc. announced the favorable findings of its Phase 2 clinical research of ABP-450 for the management of cervical dystonia. All doses of ABP-450 in the research showed rather long-term benefits, with a median duration of impact of at least 20 weeks across all dosing groups at the patients' last visit.

Key Highlights:

• The estimated prevalence of cervical dystonia ranges between 5 and 30 cases per 100,000 persons.
• According to studies, 19-39% of patients stopped working owing to cervical dystonia, while 58-69% of those who did reported lower work productivity as a result of the condition.
• Several investigations on cervical dystonia found an approximate 2:1 ratio of female to male.
• Cervical dystonia affects around 60,000 persons in the United States.

Drugs:

BOTOX is an acetylcholine release inhibitor and neuromuscular blocking medication used to treat cervical dystonia in adults. It reduces the severity of aberrant head posture and neck pain associated with this condition.

DAXXIFY (DaxibotulinumtoxinA-lanm) injection refers to an acetylcholine release inhibitor and neuromuscular blocking agent used to treat cervical dystonia in adults. DAXXIFY is based on Revance's proprietary Peptide Exchange Technology, a synthetic, 35-amino-acid stabilizing excipient that is free of human serum albumin and animal-derived components.

ABP-450 comprises a 900 kDa botulinum toxin type-A complex generated by the bacteria Clostridium botulinum. When injected at therapeutic levels, ABP-450 inhibits peripheral acetylcholine release at presynaptic cholinergic nerve terminals by breaking down SNAP-25, a protein required for successful docking and discharge of acetylcholine from vesicles within nerve endings, resulting in muscle denervation and relaxation.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cervical dystonia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cervical dystonia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cervical dystonia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cervical dystonia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the cervical dystonia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the cervical dystonia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of cervical dystonia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cervical dystonia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cervical dystonia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with cervical dystonia across the seven major markets?
• What is the size of the cervical dystonia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of cervical dystonia?
• What will be the growth rate of patients across the seven major markets?
   

Cervical Dystonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cervical dystonia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cervical dystonia market?
• What are the key regulatory events related to the cervical dystonia market?
• What is the structure of clinical trial landscape by status related to the cervical dystonia market?
• What is the structure of clinical trial landscape by phase related to the cervical dystonia market?
• What is the structure of clinical trial landscape by route of administration related to the cervical dystonia market?